Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: June 29, 2006
Last updated: June 28, 2009
Last verified: June 2006
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity

Condition Intervention Phase
Retinopathy of Prematurity
Drug: intravitreal injection
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Clinical appearance

Study Start Date: July 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   1 Month to 12 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346814

Contact: Hugo Quiroz-Mercado, MD 525510841400 ext 1171
Contact: Maria A Martínez-Castellanos, MD 525510841400 ext 1171

Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes" Recruiting
Mexico City, Mexico DF, Mexico, 04030
Contact: Maria A Martinez-Castellanos, MD    525510841400 ext 1171   
Principal Investigator: Maria Martinez-Castellanos, MD         
Sub-Investigator: Hugo A Quiroz-Mercado, MD         
Sub-Investigator: Myriam L Hernandez-Rojas, MD         
Sub-Investigator: Jans Fromow-Guerra, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Maria Martínez-Castellanos, MD APEC
  More Information

No publications provided Identifier: NCT00346814     History of Changes
Other Study ID Numbers: APEC-001
Study First Received: June 29, 2006
Last Updated: June 28, 2009
Health Authority: Mexico: Ministry of Health

Keywords provided by Asociación para Evitar la Ceguera en México:
Retinopathy of prematurity
antiangiogenic therapy

Additional relevant MeSH terms:
Retinal Diseases
Retinopathy of Prematurity
Eye Diseases
Infant, Newborn, Diseases
Infant, Premature, Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 27, 2015